Mitotech S.A. is a Luxembourg-based clinical stage biotechnology company developing novel drugs for treatment of predominantly age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria directed cardiolipin peroxidation inhibitors. Company’s lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases.
Products & services
Company’s most clinically advanced drug formulation is Visomitin – ophthalmic solution of SkQ1 developed for several age-related eye disorders, including Dry Eye Disease, where Mitotech reached Phase 3 clinical stage in the U.S. Mitotech is also approaching clinical stage of development of its oral drug formulation for treatment of Multiple Sclerosis, Alzheimer’s Disease and other disorders.
Print this page Send by email